G1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023 [Yahoo! Finance]
G1 Therapeutics, Inc. (GTHX)
Last g1 therapeutics, inc. earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
g1therapeutics.com/pages/investors/investors.htm
Company Research
Source: Yahoo! Finance
Fourth Quarter Performance : The company reported a 29% growth in net COSELA revenue in Q4 2023, reaching $13.9 million. Operational Efficiency : Operating expenses significantly reduced, contributing to a lower net loss compared to the previous year. Research and Development : R&D expenses decreased as the company focused on ongoing clinical trials, including the pivotal PRESERVE 2 trial. 2024 Revenue Guidance : G1 Therapeutics provided a net revenue guidance of $60 to $70 million for COSELA in 2024. Financial Position : The company ended 2023 with $82.2 million in cash, cash equivalents, and marketable securities, extending its cash runway into 2025. Warning! GuruFocus has detected 4 Warning Signs with GTHX. G1 Therapeutics Inc ( NASDAQ:GTHX ), a commercial-stage biopharmaceutical company, released its 8-K filing on February 28, 2024, detailing its financial results for the fourth quarter and full year of 2023. The company, known for developing novel therapies for cance
Show less
Read more
Impact Snapshot
Event Time:
GTHX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GTHX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GTHX alerts
High impacting G1 Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GTHX
News
- G1 Therapeutics First Quarter 2024 Earnings: Revenues Disappoint [Yahoo! Finance]Yahoo! Finance
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.MarketBeat
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- G1 Therapeutics, Inc. (NASDAQ: GTHX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $12.00 price target on the stock.MarketBeat
- G1 Therapeutics and Pepper Bio sign license agreement for lerociclib [Seeking Alpha]Seeking Alpha
GTHX
Earnings
- 5/1/24 - Miss
GTHX
Sec Filings
- 5/1/24 - Form 10-Q
- 5/1/24 - Form 8-K
- 4/25/24 - Form ARS
- GTHX's page on the SEC website